These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 18154669)

  • 1. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.
    Pickard AS; Neary MP; Cella D
    Health Qual Life Outcomes; 2007 Dec; 5():70. PubMed ID: 18154669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of FACT- and EQ-5D-based utility scores in cancer.
    Pickard AS; Ray S; Ganguli A; Cella D
    Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
    Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
    Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of minimally important differences in the EQ-5D and SF-6D indices and their utility in stroke.
    Kim SK; Kim SH; Jo MW; Lee SI
    Health Qual Life Outcomes; 2015 Mar; 13():32. PubMed ID: 25889191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P.
    Murasawa H; Sugiyama T; Matsuoka Y; Okabe T; Hino A; Tanaka N; Sugimoto M; Oyama M; Fujimoto K; Horie S; Noto S; Shimozuma K
    Qual Life Res; 2019 Sep; 28(9):2383-2391. PubMed ID: 31025290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease.
    Bae E; Choi SE; Lee H; Shin G; Kang D
    BMC Pulm Med; 2020 Mar; 20(1):73. PubMed ID: 32293387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany.
    Stark RG; Reitmeir P; Leidl R; König HH
    Inflamm Bowel Dis; 2010 Jan; 16(1):42-51. PubMed ID: 19475674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments.
    Luo N; Johnson J; Coons SJ
    Med Care; 2010 Apr; 48(4):365-71. PubMed ID: 20355266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?
    Huang IC; Willke RJ; Atkinson MJ; Lenderking WR; Frangakis C; Wu AW
    Qual Life Res; 2007 Aug; 16(6):1065-72. PubMed ID: 17415683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The responsiveness of EQ-5D utility scores in patients with depression: A comparison with instruments measuring quality of life, psychopathology and social functioning.
    Günther OH; Roick C; Angermeyer MC; König HH
    J Affect Disord; 2008 Jan; 105(1-3):81-91. PubMed ID: 17532051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
    Meregaglia M; Borsoi L; Cairns J; Tarricone R
    Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D.
    Walters SJ; Brazier JE
    Qual Life Res; 2005 Aug; 14(6):1523-32. PubMed ID: 16110932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
    McClure NS; Sayah FA; Xie F; Luo N; Johnson JA
    Value Health; 2017 Apr; 20(4):644-650. PubMed ID: 28408007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics.
    Trippoli S; Vaiani M; Lucioni C; Messori A
    Pharmacoeconomics; 2001; 19(8):855-63. PubMed ID: 11596837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer.
    Pickard AS; Jiang R; Lin HW; Rosenbloom S; Cella D
    Clin Ther; 2016 Apr; 38(4):769-77. PubMed ID: 27041407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study.
    Takemoto ML; Lopes da Silva N; Ribeiro-Pereira AC; Schilithz AO; Suzuki C
    Health Qual Life Outcomes; 2015 Aug; 13():119. PubMed ID: 26246238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing UK, USA and Australian values for EQ-5D as a health utility measure of oral health.
    Brennan DS; Teusner DN
    Community Dent Health; 2015 Sep; 32(3):180-4. PubMed ID: 26513855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correspondence between EQ-5D health state classifications and EQ VAS scores.
    Whynes DK;
    Health Qual Life Outcomes; 2008 Nov; 6():94. PubMed ID: 18992139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of the EQ-5D in patients with irritable bowel syndrome.
    Bushnell DM; Martin ML; Ricci JF; Bracco A
    Value Health; 2006; 9(2):90-7. PubMed ID: 16626412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimally Important Difference of the EQ-5D-5L Index Score in Adults with Type 2 Diabetes.
    McClure NS; Sayah FA; Ohinmaa A; Johnson JA
    Value Health; 2018 Sep; 21(9):1090-1097. PubMed ID: 30224114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.